Earnings call Recursion reported a transformative quarter marked by its initial clinical proof of concept for FAP, a 35% YoY reduction in pro forma operating expenses, and $754 million in year-end ...
CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, emphasizing its capability to improve efficiency in drug discovery and development. Management ...
Welcome everybody to Recursion's Earnings Call. I'm Chris Gibson, Co-Founder and CEO, and I'm excited to take you through Recursions 2024, 2025 and the time ahead. So with that we'll jump into the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results